Liver function study for capivasertib: a safety check
NCT ID NCT07343960
First seen Jan 15, 2026 · Last updated May 28, 2026 · Updated 19 times
Summary
This study looks at how the drug capivasertib is processed in people with moderate liver impairment compared to those with healthy livers. About 20 adults will receive a single dose, and researchers will measure drug levels and safety. The goal is to understand dosing needs for patients with liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE HEPATIC IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGRialto, California, 92377, United States
-
Research Site
RECRUITINGSan Antonio, Texas, 78215, United States
Conditions
Explore the condition pages connected to this study.